Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

ICYMI: What the experts are saying about importation

March 23, 2017

Importation - FDA commissioners and other stakeholder comments

Read More

Guest Post: The importance of a modern FDA in drug discovery

March 22, 2017

A swift passage of PDUFA VI will maximize the potential of 21st century medicine and ensure that every related decision is in the best interest of patients.

Read More

PhRMA Statement on FDA User Fees

March 22, 2017

PhRMA president and CEO Stephen J. Ubl issued a statement in support of the U.S. Food and Drug Administration’s (FDA) user fee programs the Prescription Drug User Fee Act (PDUFA) VI, Biosimilar User Fee Act (BsUFA) II and the Generic Drug User Fee Act (GDUFA) II.

Read More

PhRMA Statement on NAFTA Tribunal Decision in the Eli Lilly Case

March 21, 2017

PhRMA issued statement on the NAFTA Tribunal Decision in the Eli Lilly Case.

Read More

Medicare Monday: Billing code basics for biologics in Part B

March 20, 2017

MedPAC's consolidated billing proposal would put access to important Part B medicines at risk.

Read More

How drug importation schemes could increase U.S. law enforcement burdens

March 16, 2017

A few examples of how drug trafficking and importation proposals can impact law enforcement.

Read More

Medicare Monday: A closer look at Part B spending

March 13, 2017

Putting Part B drug spending growth in the context of overall program spending.

Read More

PhRMA Statement on Dr. Scott Gottlieb’s Nomination to Lead the U.S. Food and Drug Administration

March 10, 2017

Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement on President Trump’s nomination of Dr. Scott Gottlieb to lead the U.S. Food and Drug Administration (FDA).

Read More

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care

March 6, 2017

A recent white paper takes a deeper look at how reforms focused on Stark and Anti-Kickback could help the move toward value-driven health care.

Read More

Medicare Monday: New study further confirms increased use of generics after Part D

March 6, 2017

There has been a steady increase year after year in the generic utilization rate for Part D beneficiaries.

Read More
prev 1 2 3 4 5 6 next